Pharmacy benefit managers, including companies like Express Scripts and CVS Health, scored a victory in a court case determining whether a state law that required disclosure of generic drug pricing is invalid because it is preempted by federal law.
The U.S. Court of Appeals for the Eighth Circuit held June 8 that an Arkansas law that set a floor on prices that PBMs can pay to pharmacies for generic drugs is preempted by both ERISA and the Medicare Part D drug benefit program.
The decision is the latest development in a series of challenges on behalf of the Pharmaceutical Care ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.